CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

ABSTRACT:

Background

Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis.

Methods

Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). The plasmatic level of CXCL7 at baseline was correlated with progression-free survival (PFS).

Results

The cut-off value of CXCL7 for PFS was 250 ng ml^-1. Patients with CXCL7 plasmatic levels above the cut-off at baseline (250 ng ml^-1) had a significantly longer PFS (hazar

SUBMITTER: Dufies M 

PROVIDER: S-EPMC5625677 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature